Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial
Bob W. van Oosten(Amsterdam Neuroscience), Chris H. Polman(Vrije Universiteit Amsterdam), Alan McDougall, Suzanne Hodgkinson(UNSW Sydney), Frederik Barkhof(Netherlands Institute for Neuroscience), Alan J. Thompson(Queen Mary University of London), John McLeod, Mitchell K.P. Lai(National University of Singapore), Derek Miller(Washington University in St. Louis), I. F. Moseley(University of Amsterdam), Peter Rudge(NIHR Queen Square Dementia Biomedical Research Unit), H. J. Adèr(Vrije Universiteit Amsterdam)
Cited by 268
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k